This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Creatine Monohydrate as Adjuvant Therapy for Bipolar Depression

This study is currently recruiting participants.
See Contacts and Locations
Verified December 2015 by Ricardo Alexandre Toniolo, University of Sao Paulo
Information provided by (Responsible Party):
Ricardo Alexandre Toniolo, University of Sao Paulo Identifier:
First received: July 29, 2012
Last updated: December 1, 2015
Last verified: December 2015
The purpose of this study is to determine whether creatine monohydrate is effective as an adjuvant treatment for bipolar depression.

Condition Intervention Phase
Bipolar I Disorder Current Episode Depressed Dietary Supplement: creatine monohydrate Dietary Supplement: placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Creatine Monohydrate as Adjunctive Therapy for Bipolar Depression

Resource links provided by NLM:

Further study details as provided by Ricardo Alexandre Toniolo, University of Sao Paulo:

Primary Outcome Measures:
  • MADRS (Montgomery-Asberg depression Rating Scale) [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • HDRS-17 (Hamilton Depression Rating Scale - 17-item version) [ Time Frame: 6 weeks ]

Other Outcome Measures:
  • CGI (Clinical Global Impressions Scale) - Severity and Improvement [ Time Frame: 6 weeks ]
  • YMRS (Young Mania Rating Scale) [ Time Frame: 6 weeks ]

Estimated Enrollment: 44
Study Start Date: July 2012
Estimated Study Completion Date: July 2016
Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: creatine monohydrate
6g qd for 6 weeks
Dietary Supplement: creatine monohydrate
Placebo Comparator: placebo
6g qd for 6 weeks
Dietary Supplement: placebo


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Individuals eligible for the study will be adults aged 18 to 60 years of age who met DSM-IV criteria assessed by the SCID (Structural Clinical Interview for DSM-IV) for type I bipolar disorder, current episode depressed.
  • Patients who have scored > 19 on the Montgomery-Asberg Depression Rating Scale (MADRS) will be included, although more than two weeks of treatment with lithium (serum level> 0.8 mEq / L), valproate (serum levels> 50 mg / L) or quetiapine (300-600mg/dia dose) or drug combination.
  • Antipsychotics, anticonvulsants, benzodiazepines, and thyroid supplementation will be allowed if the dose has remained stable over the past two weeks.
  • Antidepressants will be allowed if the dosage has remained stable for 4 weeks.

Exclusion Criteria:

  • Subjects with substance abuse within 2 weeks before inclusion or substance dependence up to 2 months will not be included.
  • Other exclusion criteria will be:

    • diagnosis of schizophrenia,
    • dementia,
    • delirium,
    • epilepsy,
    • mental retardation,
    • clinically unstable medical illnesses,
    • preexisting renal disease,
    • history of hypersensibility to creatine.
  • Not included are individuals at high risk for suicidal or homicidal behavior or self-mutilation will not be included.
  • Women with gestational potential can only be included if they are using reliable contraception.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01655030

Contact: Ricardo Toniolo, MD 55 11 26617928

Institute of Psychiatry - HC-FMUSP Recruiting
Sao Paulo, SP, Brazil, 01060-970
Sponsors and Collaborators
University of Sao Paulo
Principal Investigator: Beny Lafer, PhD Bipolar Disorder Research Program, Coordinator, IPq-HC-FMUSP
  More Information

Responsible Party: Ricardo Alexandre Toniolo, MD, University of Sao Paulo Identifier: NCT01655030     History of Changes
Other Study ID Numbers: CR-BD-RCT
Study First Received: July 29, 2012
Last Updated: December 1, 2015

Additional relevant MeSH terms:
Bipolar Disorder
Behavioral Symptoms
Bipolar and Related Disorders
Mental Disorders processed this record on September 19, 2017